Ocugen – Consensus Indicates Potential 210.3% Upside

Broker Ratings

Ocugen found using ticker (OCGN) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 1 and 0.7 calculating the average target price we see 0.9. With the stocks previous close at 0.29 this is indicating there is a potential upside of 210.3%. There is a 50 day moving average of 0.31 and the 200 day MA is 0.34. The company has a market cap of $130m. Find out more information at: http://www.ocugen.com

Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company’s pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index